Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice-Reference-Cited by-同舟云学术

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice

Published:2022-11-29 Issue:12 Volume:6 Page:e813
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Delforge Michel¹,Vekemans Marie-Christiane²,Depaus Julien³,Meuleman Nathalie⁴,Van de Velde Ann⁵⁶,Vande Broek Isabelle⁷,Vandervennet Sophie⁸,Van Hoorenbeeck Sandra⁸,Moorkens Evelien⁸,Strens Danielle⁹,Diels Joris¹⁰,Ghilotti Francesca¹¹,Haefliger Benjamin¹²,Dalhuisen Sander¹³,Deraedt William¹⁰,Anguille Sébastien⁵¹⁴

Affiliation:

1. Universitaire Ziekenhuizen Leuven, Belgium

2. Cliniques Universitaires Saint-Luc, Brussels, Belgium

3. Department of Haematology, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

4. Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

5. Division of Hematology and Center for Cell Therapy & Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium

6. Heilig Hartziekenhuis, Lier, Belgium

7. AZ Nikolaas, Haematology, Sint-Niklaas, Belgium

8. Janssen-Cilag NV, Beerse, Belgium

9. Realidad bvba, Grimbergen, Belgium

10. Janssen Pharmaceutica NV, Beerse, Belgium

11. Janssen-Cilag SpA, Cologno Monzese, Italy

12. Cilag GmbH International, Zug, Switzerland

13. Janssen-Cilag BV, Breda, the Netherlands

14. Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium

Publisher

Wiley

Subject

Hematology

Reference11 articles.

1. Multiple myeloma: practice patterns across Europe;Raab;Br J Haematol.,2016

2. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy;Gandhi;Leukemia.,2019

3. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†;Dimopoulos;Ann Oncol Off J Eur Soc Med Oncol.,2021

4. Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent and daratumumab;Mehra;J Clin Oncol.,2020

5. CARTITUDE-1: Phase 1b/2 study of Ciltacabtagene Autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma;Madduri;Blood,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Steady‐state versus chemotherapy‐based hematopoietic cell mobilization after anti‐CD38‐based induction therapy in newly diagnosed multiple myeloma;Transfusion;2023-10-18

2. Decentralised, point-of-care CAR-T for multiple myeloma;The Lancet Oncology;2023-08